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Abstract
Background: Calcitonin is used as a treatment to reduce the blood calcium concentration in
hypercalcemia and to improve bone mass in osteoporosis. An analgesic effect of calcitonin has been
observed and reported in clinical situations. Ovariectomaized (OVX) rats exhibit the same
hormonal changes as observed in humans with osteoporosis and are an animal model of
postmenopousal osteoporosis. The aim of this study to investigate antinociceptive effect of
calcitonin in OVX rats using the immunohistochemical study.
Methods: We assessed the antinociceptive effects of calcitonin in an ovariectomized (OVX) rat
model, which exhibit osteoporosis and hyperalgesia, using the immunohistochemical method.
Fifteen rats were ovariectomized bilaterally, and ten rats were received the same surgery expected
for ovariectomy as a sham model. We used five groups: the OVX-CT (n = 5), the sham-CT (n =
5), and the OVX-CT-pcpa (n = 5) groups recieved calcitonin (CT: 4 U/kg/day), while OVX-vehi (n
= 5) and the sham-vehi (n = 5) groups received vehicle subcutaneously 5 times a week for 4 weeks.
The OVX-CT-pcpa-group was given traperitoneal injection of p-chlorophenylalanine (pcpa; an
inhibitor of serotonin biosynthesis) (100 mg/kg/day) in the last 3 days of calcitonon injection. Two
hours after 5% formalin (0.05 ml) subcutaneously into the hind paw, the L5 spinal cord were
removed and the number of Fos-immunoreactive (ir) neurons were evaluated using the Mann-
Whitney-U test.
Results: The numbers of Fos-ir neurons in the OVX-CT and sham-CT groups were significantly
less than in the OVX-vehi and sham-vehi groups, respectively (p = 0.0090, p = 0.0090). The number
of Fos-ir neurons in the OVX-CT-pcpa-group was significantly more than that of the OVX-CT-
group (p = 0.0283), which means pcpa inhibits calcitonin induced reduction of c-Fos production.
Conclusion: The results in this study demonstrated that 1) the increase of c-Fos might be related
to hyperalgesia in OVX-rats. 2) Calcitonin has an antinociceptive effect in both OVX and sham rats.
3) The central serotonergic system is involved in the antinociceptive properties of calcitonin.
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Background
Calcitonin is a polypeptide hormone that is secreted into
the general circulation by the parafollicular cells of the
mammalian thyroid gland, and it regulates the blood cal-
cium concentration and bone metabolism by acting on
osteoclasts. Calcitonin is used as a treatment to reduce the
blood calcium concentration in hypercalcemia and to
improve bone mass in osteoporosis. An analgesic effect of
calcitonin has been observed and reported in clinical situ-
ations, and in randomized controlled studies calcitonin
has been found to produce an analgesic effect in patients
with osteoporotic vertebral compression fractures [1,2],
reflex sympathetic dystrophy [3], and cancer pain [4].
Menopause is well known to be one of the essential causes
of osteoporosis in human [5], and since the most impor-
tant change following menopause is the depression of
estrogen, which regulate expression of various genes [6],
depletion of estrogen decreases the amounts of gene prod-
ucts, including receptors and peptides, required for mod-
ulation of nociceptive transmission. Ovariectomaized
(OVX) rats exhibit the same hormonal changes as
observed in humans with osteoporosis and are an animal
model of postmenopausal osteoporosis. OVX rats have
been used to evaluate the therapeutic effect of analgesic
drugs [7]. A significant reduction in the latencies of tail
withdrawal from hot water [8] and long-term formalin-
induced licking [9] has also been reported in OVX rats,
and because of this OVX is thought to induce hyperalgesia
in rats.
The c-fos proto-oncogene is one of the immediate-early
genes, and its expression by both noxious and non-nox-
ious stimuli [10]. It encodes a nuclear phosphoprotein, c-
Fos, that acts as a transcription factor by binding to DNA
or DNA-binding proteins in the promoter region. C-Fos is
expressed in postsynaptic neurons of the dorsal horn of
the spinal cord at an early stage of nociception, and tem-
porarily in response to various stimuli from primary affer-
ent neurons, and its level of expression depends on the
types and strength of the stimuli [11-14]. C-Fos expres-
sion is inhibited by applications of morphine and non-
steroidal anti-inflammatory drugs (NSAIDs) [15-18].
Because of these facts, the c-Fos expression in spinal cord
neurons has been used as a functional marker of nocicep-
tion in many studies [11,15-19]. The aim of the present
study was to assess the hyperalgesia in OVX rats and the
antinociceptive effect of calcitonin in OVX rats by measur-
ing the c-Fos expression as a marker of nociception.
Methods
Twenty-five female Sprague-Dawley rats (200–250 g)
were used. The experiment was performed with the
approval of the Animal Research Committee of the Fuku-
shima Medical University, and the animals were cared for
in the Experimental Animal Center of Fukushima Medical
University.
The rats were anesthetized by inhalation of ethyl ether
(99%, Diethyl Ether, Wako Pure Chemical Industries,
Ltd., Osaka, Japan). Bilateral ovariectomy was performed
according to the method reported by Shibata K et al [20]
to create an OVX model. Rats whose ovaries were exposed
but not excised were used as a sham model. The opera-
tions and drug administrations were performed according
to the schedule shown in the Figure 1. Four weeks after
surgery, a synthetic derivate of eel calcitonin, ([Asu1'7]eel
calcitonin) (4 U/kg/day) (Elcatonin, Asahi Kasei Co.,
Tokyo, Japan) was subcutaneously injected into the back
of rats 5 times a week for 4 weeks. The vehicle was injected
as a control. P-chlorophenylalanine (PCPA; Sigma, MO,
USA), 100 mg/kg/day, an inhibitor of serotonin biosyn-
thesis, was intraperitoneally injected on the final 3 days of
calcitonin administration. Normal saline was injected as a
control. The following 5 groups were established: a) a
group repeatedly subcutaneously injected with calcitonin
after OVX (OVX-calcitonin group, n = 5), b) a group
repeatedly subcutaneously injected with vehicle after OVX
(OVX-vehicle group, n = 5), c) a group intraperitoneally
injected with PCPA after OVX in addition to being repeat-
edly subcutaneously injected with of calcitonin (OVX-cal-
citonin-PCPA group, n = 5), d) a group repeatedly
subcutaneously injected with calcitonin after sham opera-
tion (sham-calcitonin group, n = 5), and e) a group
repeatedly subcutaneously injected with vehicle after
sham operation (sham-vehicle group, n = 5). After surgery
and injections, the formalin test was performed as an
acute noxious stimulus with subcutaneously injected with
5% formalin (0.050 ml) (Wako Pure Chemical Industries,
Ltd. Osaka, Japan) into the left hind paw. All rats were per-
fused two hours after formalin test.
C-Fos immunohistochemistry
The samples of spinal cord were prepared and immuno-
histochemically stained by methods based on those
described by Hamba et al [19]. Two hours after the forma-
lin test, the rats were deeply anesthetized with ethyl ether
and they intracardially perfused with 200 ml of a 4% para-
formaldehyde-0.1 M phosphate buffer (PBS) solution.
After perfusion, the L5 segment of spinal cord was excised.
The spinal cord was immersed in the 4% paraformalde-
hyde-0.1 M PBS solution for one hour, then in a 10%
sucrose-PBS solution for 24 hours, and finally in a 20%
sucrose-PBS solution for 24 hours. A 40-μm frozen section
was then cut with a microtome. It was collected as a float-
ing section in 0.1 M PBS, and it was immersed in 0.1 M
PBS containing 0.2%Triton X for three days. All sections
were immunostained for c-Fos protein by the avidin-
biotin peroxidase (ABC) technique with commercial ABC
kits (Vector Labs, Burlingame, CA). To eliminate confu-BMC Musculoskeletal Disorders 2008, 9:164 http://www.biomedcentral.com/1471-2474/9/164
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sion between small immunoreactive neurons and red
blood cells, the protocol included hydrogen peroxide pre-
treatment. The sections were incubated in a solution of
normal goat serum and then for 48 hours at 4°C in pri-
mary antiserum, which was a rabbit polyclonal antibody
directed against a synthetic peptide that corresponded to
the N-terminal of the c-Fos protein (Santa Cruz biotech-
nology, Inc., CA, USA) at a dilution of 1:3000. The reac-
tion was visualized with 0.006% hydrogen peroxide and
0.02% diaminobenzidine (DAB, Wako Pure Chemical
Industries, Ltd. Osaka, Japan). Tissue sections were thor-
oughly rinsed with Tris buffer, mounted onto MAS-coated
slides (Matsunami Grass Industries, Ltd. Osaka, Japan),
dried, dehydrated in a graded alcohol series, cleared in
xylene and coverslipped.
Quantitation of c-Fos immunoreactive neurons
All sections were digitized with a CCD camera (Axio Cam
Mrc, Carl Zeiss, Hallbergmoos, Germany) equipped with
a computer-assisted image analysis system (KS 100 imag-
ing system, Carl Zeiss, Hallbergmoos, Germany). All data
analysis procedures were performed blindly with respect
to the experimental condition of the animal. The five sec-
tions from each rat that containing highest numbers of c-
Fos immunoreactive neurons were selected for analysis.
The spinal cord was divided into 3 regions [21]: (1) lami-
nae I–II (the superficial laminae); (2) laminae III–IV (the
nucleus proprius); (3) laminae V–VI (the neck of the dor-
sal horn), and the average number of c-Fos immunoreac-
tive neurons in each region was calculated by averaging
the counts made in the five sections from each rat.
Statistical analysis
Comparisons between the numbers of c-Fos immunoreac-
tive neurons in two groups were made by the Mann-Whit-
ney's U test. A p-value less than 0.05 was considered
indicative of a statistically significant difference.
Results
c-Fos expression in laminae I–II of the dorsal horn of the 
spinal cord
Figure 2 shows illustrative cases of c-Fos immunoreactive
neurons in each of the groups. The number of c-Fos
immunoreactive neurons in the OVX-vehicle group was
significantly greater than in the sham-vehicle group (p =
0.0367; Figure 3), indicating that OVX in rats result in a
greater number of neurons in dorsal horn of the spinal
cord that produce c-Fos after formalin test. There were sig-
nificantly fewer c-Fos immunoreactive neurons in the
OVX-calcitonin group than in the OVX-vehicle group (p =
0.0090; Figure 4), and significantly fewer c-Fos immuno-
reactive neurons in the sham-calcitonin group than in the
sham-vehicle group (p = 0.0090; Figure 5). These findings
mean that repeated calcitonin injection of both the OVX
Ovariectomy or a sham operation was performed in each group, and from postoperative week 4 onward calcitonin or vehicle  was injected 5 times a week for 4 weeks Figure 1
Ovariectomy or a sham operation was performed in each group, and from postoperative week 4 onward calci-
tonin or vehicle was injected 5 times a week for 4 weeks. PCPA was injected on the final 3 days of calcitonin injection. 
A formalin test was conducted in postoperative week 8, and two hours later, the animals in each group were perfused, and tis-
sue was removed.
Groups
OVX-calcitonin group 
OVX-vehicle group 
OVX-calcitonin-PCPA group 
Sham-calcitonin group 
Sham-vehicle groupBMC Musculoskeletal Disorders 2008, 9:164 http://www.biomedcentral.com/1471-2474/9/164
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rats and the sham-operated rats result in fewer neurons in
the dorsal horn of spinal cord that produced c-Fos after
the formalin test. There were significantly more c-Fos
immunoreactive neurons in the OVX-calcitonin-PCPA
group than in the OVX-calcitonin group (p = 0.0283; Fig-
ure 6), but the difference from the OVX-vehicle group was
not significant (Figure 6), indicating that the effect of
repeated doses of calcitonin that decreases the number of
c-Fos-producing neurons after the formalin test was abol-
ished when the serotonin synthesis inhibitor was admin-
istered.
c-Fos expression in laminae III–IV and laminae V–VI
The results of the comparison between groups of c-Fos
expression in laminae III–IV and laminae V–VI were sim-
ilar to the results in laminae I–II, however, the only statis-
tically significant difference was between the sham-
calcitonin group and the sham-vehicle group. Significant
differences in the numbers of c-Fos immunoreactive neu-
rons in laminae III–IV and laminae V–VI were observed
only between the sham-calcitonin group and the sham-
vehicle group (laminae III–IV; p = 0.0163, laminae V–VI;
p = 0.0163; Figure 7), indicating that the numbers of neu-
rons that produced c-Fos after the formalin test in the
sham-operated rats were decreased by calcitonin adminis-
tration.
Discussion
Subcutaneous injection of the rat hind paw with formalin
is known to produce a biphasic response consisting of an
early intense response (early phase) in the first five min-
utes, and a later moderate response (late phase) that is
lasts from 20 to 60 min after the injection. The nociceptive
response to formalin injection is matched by a corre-
sponding biphasic increase in the activity of dorsal horn
neurons after the injection [22]. The early phase is
thought to be caused by stimulation of the peripheral
nerve by the formalin, and the late phase is thought to be
attributable to the secondary inflammation in the tissues
[23]. C-fos mRNA was observed in the spinal cord after
the formalin test, and expression peaked at 15–30 min-
utes in the superficial laminae of dorsal horn (laminae I–
II) and at 30–60 minutes in the deep laminae (laminae V–
VI). The expression of c-fos mRNA in those lesions
Photomicrographs of transverse sections of L5 level of the lumbar spinal cord illustrating the distribution of c-Fos immunore- active neurons in the dorsal horn in the OVX-vehicle group (a), OVX-calcitonin group (b), OVX-calcitonin-PCPA group (c),  sham-vehicle group (d), and sham-calcitonin group (e) Figure 2
Photomicrographs of transverse sections of L5 level of the lumbar spinal cord illustrating the distribution of c-
Fos immunoreactive neurons in the dorsal horn in the OVX-vehicle group (a), OVX-calcitonin group (b), 
OVX-calcitonin-PCPA group (c), sham-vehicle group (d), and sham-calcitonin group (e). Scale bar, 100 μm. The 
Figure shows a section of dorsal horn at the L5 level [21].BMC Musculoskeletal Disorders 2008, 9:164 http://www.biomedcentral.com/1471-2474/9/164
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appears to correspond to the early phase and the late
phase of the response to the formalin test [24]. Altogether
the appearance of c-Fos immunoreactive neurons in the
superficial laminae of the dorsal horn shows the sensitiza-
tion of post synaptic neurons after stimulation of periph-
eral nerve by formalin, indicating that direct transmission
process of acute noxious stimulus. In the other hand, the
appearance of c-Fos immunoreactive neurons in the deep
laminae of the dorsal horn represents transmission of sec-
ondarily tissue inflammation.
In the present study the number of c-fos immunoreactive
neurons in the dorsal horn of the spinal cord increased in
response to the acute noxious stimulus in the OVX rats,
particularly in the superficial lamina of the dorsal horn,
indicating that OVX enhances nociception in rats. The
Expression in laminae I–II: OVX-vehicle group vs sham-vehi- cle group Figure 3
Expression in laminae I–II: OVX-vehicle group vs 
sham-vehicle group. The number of c-Fos immunoreac-
tive neurons in the OVX-vehicle group was significantly 
greater than in the sham-vehicle group (p = 0.0367).
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Expression in laminae I–II: OVX-calcitonin group vs OVX- vehicle group Figure 4
Expression in laminae I–II: OVX-calcitonin group vs 
OVX-vehicle group. There were significantly fewer c-Fos 
immunoreactive neurons in the OVX-calcitonin group than 
in the OVX-vehicle group (p = 0.0090).
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Expression in laminae I–II: Sham-calcitonin group vs sham- vehicle group Figure 5
Expression in laminae I–II: Sham-calcitonin group vs 
sham-vehicle group. There were significantly fewer c-Fos 
immunoreactive neurons in the sham-calcitonin group than in 
the sham-vehicle group (p = 0.0090).
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Expression in laminae I–II: OVX-calcitonin-pcpa group vs  OVX-calcitonin group and OVX-vehicle group Figure 6
Expression in laminae I–II: OVX-calcitonin-pcpa 
group vs OVX-calcitonin group and OVX-vehicle 
group. There were significantly more c-Fos immunoreactive 
neurons in the OVX-calcitonin-PCPA group than in the 
OVX-calcitonin group (p = 0.0283), but the difference from 
the OVX-vehicle group was not significant (p = 0.4034).
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mechanism of the hyperalgesia has not been well docu-
mented, although there have been some reports of hyper-
algesia in OVX rat in behavioral studies [7,20,25]. A
significant decline in estrogen hormone is known as a
result of OVX [5]. Estrogen forms complexes with its
receptors and controls expression of various genes by
binding to specific sequences in the promoter region of
the genes [26], and thus estrogen depletion affects the
amount of gene products, such as peptides and receptors,
associated with transmission of nociception. The number
of serotonin receptors in the presynaptic area of dorsal
horn has been reported to be decreased in OVX rats [27].
The report conjectures the fact with a disorder of the
descending inhibitory serotonergic system that induces
antinociception by inhibiting the release of neurotrans-
mitters such as somatostatin [28]. Since c-Fos is a func-
tional marker of nociception, our results indicate a change
in that the transmission of noxious stimuli to secondary
afferent neurons in OVX rats. Taken together, the results
of this study suggest that the hyperalgesia in OVX rat is
attributable to changes in the descending inhibitory sero-
tonergic system.
The results of this present study also show that the
repeated calcitonin injections have a suppressive effect
that decreases the number of c-Fos producting neurons in
the superficial laminae of the dorsal horn after the forma-
lin test. Almost all experimental studies have examined
only the acute anti-nociceptive effects of calcitonin [29-
32], and administration consisted of a single centrally
injections such as an intracerebroventricular injections
[29,31], intrathecal injection [31,32] or injection into the
periaqueductal gray matter [30]. These acute antinocicep-
tive effects were thought as acting by those binding sites in
central nervous system directry [33,34]. In clinical settings
repeated peripheral injections for a month are required to
c-Fos expression in laminae III–IV and laminae V–VI of the dorsal horn Figure 7
c-Fos expression in laminae III–IV and laminae V–VI of the dorsal horn. The results of comparison of the number of 
c-Fos immunoreactive neurons between groups in laminae III–IV and laminae V–VI were similar to the results in laminae I–II, 
however the only significant difference was between the sham-calcitonin group and the sham-vehicle group (laminae III–IV; p = 
0.0163, laminae V–VI; p = 0.0163).
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treat the pain accompanying osteoporosis [9,35]. In
behavioral studies, repeated systemic injections of calci-
tonin have been found to inhibit formalin-induced hypal-
gesia in rats, while single injections have had no effects
[36] and repeated systemic injections of calcitonin have
inhibited OVX-induced hypalgesia in rats [20]. In those
studies calcitonin was effective when it injected repeatedly
for about 4 weeks. These results are similar to the clinical
effects of calcitonin reported in patients [9,35]. According
to these facts, the duration and doses of calcitonin used in
the present study were similar to those used clinically. In
addition, it is reported in the experimental studies that the
expression of c-Fos in the dorsal horn increased and the
pain threshold decreased after formalin or yeast injection
and skin incision, and administration of NSAIDs or
anesthegia effects to improve pain threshold and inhibit
c-Fos expression in the spinal cord [36-39]. Therefore, our
results suggest that repeated systemic injection of calci-
tonin has an antinociceptive effect. However, the c-Fos
expression is related with the reaction of the formalin test
but dose not reflect the bone pain by postmenopausal
osteoporosis in this study. There are studies that calci-
tonin has the effect of reducing bone pain associated with
bone metabolic disorders, compression fracture and oste-
oporosis [1-4,40,41]. The bone pain induced by ovariec-
tomy was not investigated in this study. In addition, the
pain induced by the formalin test is quite different from
the clinical situation and tissue damage is worse than the
clinical situation. This is the limitation of this study, how-
ever, calcitonin was the effect of inhibiting formalin-
induced c-Fos expression which is a strong stimulant.
Thereby, the results in this study show the benefit of calci-
tonin treatment. There are studies that show calcitonin
has an effect on patients with osteoarthritis (OA) in the
clinical trail [42] and improves cartilage erosion in the
experimental studies [43,44]. Elderly people have possi-
bility of developing both osteoporosis and OA. Further-
more, calcitonin provides benefits of improving
osteoporosis itself, bone pain, hyperalgesia induced by
postmenopausal condition and OA. Calcitonin may pro-
vide the benefit of improving symptoms various ways. In
addition, clinical trials for calcitonin treatment on the dif-
ferent conditions of each disease are needed.
It has been reported that the decrease in number of serot-
onin receptors in OVX rats recovered after repeated injec-
tion of calcitonin, and it was concluded that the reversal
of the changes in serotonin receptors is one of the mecha-
nisms of the analgesic actions of calcitonin [27]. Together
with the results showing that calcitonin inhibits formalin-
induced hypalgesia in a rat behavioral study [45], our
results indicate that calcitonin has an antinociceptive
effect in sham-operated rats. This result suggests that the
antinociceptive mechanism of calcitonin is activation as
well as restoration of the descending inhibitory serotoner-
gic system.
The suppressive effect of calcitonin that caused the smaller
number of c-Fos-producting neurons in the dorsal horn in
our study was abolished by PCPA. The behavioral studies
also demonstrated that the calcitonin-induced antinoccic-
eption was completely inhibited by intraperitoneal injec-
tion of PCPA [21,40]. Because PCPA is an inhibitor of
serotonin biosynthesis, the amount of serotonin was
decreased and the activity of the descending inhibitory
serotonergic system was degraded after PCPA injection.
Our results indicate that the involvement of central sero-
tonergic system in the antinococeptive mechanism of cal-
citonin by immunohistochemical method, and is
congruent with the report of antinociceptive mechanism
through restoration of serotonin receptors [27].
The results in laminae III–IV and laminae V–VI were sim-
ilar to the results in laminae I–II, however, the only statis-
tically significant difference was observed between the
sham-calcitonin group and the sham-vehicle group.
Because the appearance of c-Fos in deep laminae (laminae
V–VI) represents transmission of secondary tissue inflam-
mation, our results suggest that repeated injection of cal-
citonin also has an antinociceptive effect on nociceptive
stimulation by tissue inflammation. The fact that a signif-
icant difference observed only between the sham-calci-
tonin group and sham-vehicle groups may be result of the
difference in antinociceptive effect of calcitonin between
OVX rats and sham-operated rats and between restoration
and activation of descending inhibitory serotonergic sys-
tem. Further studies are necessary to clarify the antinoco-
ceptive effect of calcitonin.
Conclusion
This is the first immunohistochemical study to investigate
hyperalgesia in OVX rats and the antinociceptive effect of
calcitonin. We concluded that the hyperalgesia in OVX rat
is attributable to changes in the descending inhibitory ser-
otonergic system, that repeated systemic administration
of calcitonin has an antinociceptive effect, and that the
descending serotonergic inhibitory system is involved in
the mechanism of its antinociceptive action.
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